Identification of this immune evasion strategy from tumour tissue biopsy staining also revealed PD-L1 to be present in varying amounts, an observation which now supports its use as a biomarker to stratify patients likely to be responsive to anti-PD-1/PD-L1 therapies [18]. This evidence concerns the gene CD274 and neoplasm.